CRIS Current Research Information System

TACCHETTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.390
EU - Europa 2.971
AS - Asia 1.074
AF - Africa 229
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 8.670
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.374
GB - Regno Unito 791
IT - Italia 532
SE - Svezia 516
CN - Cina 420
VN - Vietnam 413
DE - Germania 372
IN - India 156
IE - Irlanda 152
UA - Ucraina 127
FR - Francia 115
RU - Federazione Russa 102
TG - Togo 79
CI - Costa d'Avorio 65
ZA - Sudafrica 63
EE - Estonia 59
BG - Bulgaria 45
CH - Svizzera 41
FI - Finlandia 36
JO - Giordania 29
BE - Belgio 28
CA - Canada 15
IR - Iran 14
NG - Nigeria 14
NL - Olanda 11
JP - Giappone 10
CZ - Repubblica Ceca 9
LB - Libano 8
SC - Seychelles 8
PH - Filippine 7
AT - Austria 6
ES - Italia 6
GR - Grecia 5
IL - Israele 4
RO - Romania 4
CL - Cile 3
PL - Polonia 3
SG - Singapore 3
TR - Turchia 3
HR - Croazia 2
KR - Corea 2
PT - Portogallo 2
RS - Serbia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BD - Bangladesh 1
EC - Ecuador 1
HK - Hong Kong 1
HU - Ungheria 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MX - Messico 1
NO - Norvegia 1
SA - Arabia Saudita 1
Totale 8.670
Salva come PNG Salva come JPEG
Città #
Southend 715
Fairfield 586
Chandler 570
Ashburn 410
Woodbridge 276
Seattle 255
Wilmington 239
Ann Arbor 223
Cambridge 213
Houston 210
Dong Ket 178
Princeton 170
Dublin 152
Bologna 146
Lomé 79
Beijing 73
Jacksonville 68
Bremen 66
Westminster 66
Abidjan 65
Nanjing 64
Padova 62
New York 57
Berlin 49
Jinan 45
Sofia 45
Turin 43
San Diego 38
Shenyang 36
Helsinki 35
Saint Petersburg 34
Redwood City 33
Bern 32
Amman 29
Brussels 28
Milan 27
Redmond 26
Nanchang 25
Boardman 23
Changsha 23
Fabriano 22
Hebei 22
Florence 20
Jiaxing 19
Tianjin 17
Mülheim 15
Norwalk 15
Washington 15
Abeokuta 13
Falls Church 13
Medford 13
Dearborn 12
Monmouth Junction 12
Des Moines 11
Hangzhou 11
Olalla 10
Leawood 9
Los Angeles 9
Paris 9
Tokyo 9
Haikou 8
Kunming 8
Mahé 8
Pune 8
Rome 8
Verona 8
Salsomaggiore Terme 7
Toronto 7
Zhengzhou 7
Andover 6
Coimbatore 6
Boydton 5
Groningen 5
Guangzhou 5
Kuban 5
Raleigh 5
Riola 5
San Francisco 5
Taizhou 5
Amsterdam 4
Anoia Superiore 4
Ardabil 4
Argelato 4
Como 4
Fuzhou 4
Kilburn 4
Lanzhou 4
London 4
Ningbo 4
Romainville 4
San Lazzaro Di Savena 4
Vienna 4
Winnipeg 4
York 4
Bühl 3
Cagliari 3
Frankfurt am Main 3
Geneva 3
Jerusalem 3
Kiev 3
Totale 5.989
Salva come PNG Salva come JPEG
Nome #
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 225
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 195
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 181
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 174
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 161
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 161
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 161
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 154
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 152
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 147
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 147
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 144
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 138
Thalidomide maintenance in multiple myeloma: certainties and controversies. 137
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 133
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 133
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 130
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 130
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 128
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 128
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 126
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 125
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 124
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 121
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 118
Dermoscopy of cutaneous involvement by multiple myeloma 118
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 117
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 116
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 115
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 115
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 114
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 114
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 114
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 113
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 110
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 109
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 109
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 108
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 107
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 107
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 106
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 105
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 103
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 103
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. 103
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 103
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 101
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 101
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 101
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. 100
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 99
null 98
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 96
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 96
Role of consolidation therapy in transplant eligible multiple myeloma patients. 92
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 92
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 89
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 89
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 87
Extramedullary metastatic plasmacytoma in a multiple myeloma patient 87
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma 86
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 86
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 85
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 85
Neuropathy in multiple myeloma treated with thalidomide: a prospective study. 82
Multiple myeloma: disease response assessment 81
null 77
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 76
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. 74
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 73
Imaging in multiple myeloma: How? When? 72
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 71
Gene expression profiling (gep) of myeloma (MM) cells to predict attainment near complete response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed MM 61
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 61
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 60
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 48
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 46
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 40
null 39
The role of monoclonal antibodies in smoldering and newly diagnosed transplant-eligible multiple myeloma 34
Proteasome inhibitors: Bortezomib in multiple myeloma 31
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 29
Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma 27
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 25
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 23
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 22
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 21
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 20
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 18
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study 17
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 16
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 8
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 7
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 5
Front-line treatment of multiple myeloma 3
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 3
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 2
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 1
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 1
Totale 8.926
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.591
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.591
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019183 0 0 0 0 0 0 0 0 0 71 33 79
2019/20202.241 277 52 15 152 233 227 273 291 301 173 108 139
2020/20211.290 223 77 31 56 33 52 44 72 125 62 82 433
2021/20221.727 180 75 98 132 157 79 33 117 65 173 311 307
2022/20232.299 211 354 102 356 144 204 77 121 358 78 174 120
2023/2024693 45 114 49 59 69 187 35 95 9 31 0 0
Totale 8.926